• In January 2026, HealthEquity, Inc. issued earnings guidance for the fiscal year ending January 31, 2027, projecting revenues between US$1.38 billion and US$1.41 billion, and presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
• This combination of a clearer revenue outlook and high-profile conference exposure provided investors with fresh information about management’s expectations and positioning within the healthcare benefits space.
• We’ll now examine how HealthEquity’s new revenue guidance range could influence the company’s investment narrative over the coming periods.

AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is HealthEquity's Investment Narrative?

To own HealthEquity, you need to believe in the long-term appeal of consumer-directed healthcare accounts and the company’s ability to convert HSA growth into durable fee and custodial revenue. The new US$1.38 billion to US$1.41 billion revenue guidance, unveiled alongside management’s appearance at the J.P. Morgan Healthcare Conference, gives a clearer short-term reference point but does not radically change the near-term story by itself, especially given the share price has already retreated over the past year. The key near-term catalysts still center on execution against guidance, HSA asset yields, and the pace of new account wins. On the risk side, a rich earnings multiple, recent insider selling and any disappointment relative to this updated revenue outlook could quickly pressure sentiment further.

However, investors should pay close attention to how sensitive sentiment is to even small guidance shifts. Despite retreating, HealthEquity's shares might still be trading 47% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

The Simply Wall St Community’s four fair value estimates for HealthEquity span roughly US$97 to US$158, underscoring how widely opinions can differ. When you set that against the recent guidance and already high earnings multiple, it becomes clear that expectations are a central driver of how the stock could trade around future results.

Explore 4 other fair value estimates on HealthEquity - why the stock might be worth as much as 87% more than the current price!

Build Your Own HealthEquity Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free HealthEquity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HealthEquity's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.